Studies have shown that the level of circulating fetuin-A in MetS patients is higher than in patients without MetS, which may be a tendency to increase the risk of MetS with the increase of circulating fetuin-A concentration (Pan X. et al., 2020). This evidence concerns the gene AHSG and metabolic syndrome.